Physician profile
David D'Alessandro
NPI 1326092065
$5,646.04
in general payments reported to CMS, 2019-2025
15 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $125 · 2021: $306 · 2022: $770 · 2023: $652 · 2024: $1,220 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,113.21 | 2022-2025 | Miebo, Xiidra, Infuse |
| Glaukos Corporation | $805.59 | 2022-2025 | |
| Allergan, INC. | $707.83 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $588.79 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $567.55 | 2019-2025 | Tryptyr, Total30, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $450.96 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $446.21 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $292.97 | 2022-2024 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $248.56 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $122.83 | 2024 | Syfovre |
| Abbvie INC. | $121.97 | 2023 | Vuity |
| Sight Sciences, INC. | $120.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.51 | 2019-2021 | |
| Shire North American Group INC | $18.21 | 2019 | |
| Harrow Eye, LLC | $13.57 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David D'Alessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.